Phone: (919)-558-1323

Contact Us | Our Team


DILIsym® has been included in numerous publications. DILIsym Services remains committed to continuing to publish and present our findings where appropriate. Some examples of key publications are listed below in addition to a full bibliography.

DSS Bibliography


1: Woodhead JL, Brock WJ, Roth SE, Shoaf SE, Brouwer KL, Church R, Grammatopoulos TN, Stiles L, Siler SQ, Howell BA, Mosedale M, Watkins PB, Shoda LK. Application of a Mechanistic Model to Evaluate Putative Mechanisms of Tolvaptan Drug-Induced Liver Injury and Identify Patient Susceptibility Factors. Toxicol Sci. 2016 Sep 21. pii: kfw193. Epub ahead of print. PubMed PMID: 27655350.

2: Longo DM, Yang Y, Watkins PB, Howell BA, Siler SQ. Elucidating Differences in the Hepatotoxic Potential of Tolcapone and Entacapone With DILIsym®, a Mechanistic Model of Drug-Induced Liver Injury. CPT Pharmacometrics Syst Pharmacol. 2016 Jan;5(1):31-9. doi: 10.1002/psp4.12053. PubMed PMID: 26844013.

3: Yang Y, Nadanaciva S, Will Y, Woodhead JL, Howell BA, Watkins PB, Siler SQ. MITOsym®: A Mechanistic, Mathematical Model of Hepatocellular Respiration and Bioenergetics. Pharm Res. 2015 Jun;32(6):1975-92. doi: 10.1007/s11095-014-1591-0. Epub 2014 Dec 12. PubMed PMID: 25504454.

4: Woodhead JL, Yang K, Siler SQ, Watkins PB, Brouwer KL, Barton HA, Howell BA. Exploring BSEP inhibition-mediated toxicity with a mechanistic model of drug-induced liver injury. Front Pharmacol. 2014 Nov 7;5:240. doi: 10.3389/fphar.2014.00240. eCollection 2014. PubMed PMID: 25426072.

5: Shon J, Abernethy DR. Application of systems pharmacology to explore mechanisms of hepatotoxicity. Clin Pharmacol Ther. 2014 Nov;96(5):536-7. doi: 10.1038/clpt.2014.167. PubMed PMID: 25336266.

6: Woodhead JL, Yang K, Brouwer KL, Siler SQ, Stahl SH, Ambroso JL, Baker D, Watkins PB, Howell BA. Mechanistic Modeling Reveals the Critical Knowledge Gaps in Bile Acid-Mediated DILI. CPT Pharmacometrics Syst Pharmacol. 2014 Jul 9;3:e123. doi: 10.1038/psp.2014.21. PubMed PMID: 25006780.

7: Howell BA, Siler SQ, Watkins PB. Use of a systems model of drug-induced liver injury (DILIsym(®)) to elucidate the mechanistic differences between acetaminophen and its less-toxic isomer, AMAP, in mice. Toxicol Lett. 2014 Apr 21;226(2):163-72. doi: 10.1016/j.toxlet.2014.02.007. Epub 2014 Feb 18. PubMed PMID: 24560604.

8: Howell BA, Siler SQ, Shoda LK, Yang Y, Woodhead JL, Watkins PB. A mechanistic model of drug-induced liver injury aids the interpretation of elevated liver transaminase levels in a phase I clinical trial. CPT Pharmacometrics Syst Pharmacol. 2014 Feb 5;3:e98. doi: 10.1038/psp.2013.74. PubMed PMID: 24500662.

9: Shoda LK, Woodhead JL, Siler SQ, Watkins PB, Howell BA. Linking physiology to toxicity using DILIsym®, a mechanistic mathematical model of drug-induced liver injury. Biopharm Drug Dispos. 2014 Jan;35(1):33-49. doi: 10.1002/bdd.1878. Epub 2013 Nov 25. Review. PubMed PMID: 24214486.

10: Bhattacharya S, Shoda LK, Zhang Q, Woods CG, Howell BA, Siler SQ, Woodhead JL, Yang Y, McMullen P, Watkins PB, Andersen ME. Modeling drug- and chemical-induced hepatotoxicity with systems biology approaches. Front Physiol. 2012 Dec 14;3:462. doi: 10.3389/fphys.2012.00462. eCollection 2012. PubMed PMID: 23248599.

11: Howell BA, Yang Y, Kumar R, Woodhead JL, Harrill AH, Clewell HJ 3rd, Andersen ME, Siler SQ, Watkins PB. In vitro to in vivo extrapolation and species response comparisons for drug-induced liver injury (DILI) using DILIsym™: a mechanistic, mathematical model of DILI. J Pharmacokinet Pharmacodyn. 2012 Oct;39(5):527-41. doi: 10.1007/s10928-012-9266-0. Epub 2012 Aug 9. PubMed PMID: 22875368.

12: Woodhead JL, Howell BA, Yang Y, Harrill AH, Clewell HJ 3rd, Andersen ME, Siler SQ, Watkins PB. An analysis of N-acetylcysteine treatment for acetaminophen overdose using a systems model of drug-induced liver injury. J Pharmacol Exp Ther. 2012 Aug;342(2):529-40. doi: 10.1124/jpet.112.192930. Epub 2012 May 16. PubMed PMID: 22593093.